Search Results - "Fudio, S"

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients by Aviles, P, Altares, R, van Andel, L, Lubomirov, R, Fudio, S, Rosing, H, Márquez Del Pino, F M, Tibben, M M, Benedit, G, Nan-Offeringa, L, Luepke Estefan, X E, Francesch, A, Zeaiter, A, Cuevas, C, Schellens, J H M, Beijnen, J H

“…Lurbinectedin is a novel and potent selective inhibitor of active transcription of protein-coding genes, triggering apoptosis of cancerous cells. It has been…”
Get full text

A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients by Ramirez, E, Carcas, A J, Borobia, A M, Lei, S H, Piñana, E, Fudio, S, Frias, J

“…The detection and reporting of serious adverse drug reactions (SADRs) have become important components of monitoring and evaluation activities performed in…”
Get full text

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine by van Andel, L., Rosing, H., Lubomirov, R., Avilés, P., Fudio, S., Tibben, M.M., Nan-Offeringa, L., Schellens, J.H.M., Beijnen, J.H.

“…•A rapid and sensitive LC–MS/MS method developed to quantify lurbinectedin in human plasma and urine.•The assay has successfully been validated in the 0.1–100…”
Get full text

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine by van Andel, L., Rosing, H., Fudio, S., Avilés, P., Tibben, M.M., Gebretensae, A., Schellens, J.H.M., Beijnen, J.H.

“…•A bioanalytical assay was developed for plitidepsin in plasma, whole blood and urine using HPLC–MS/MS.•The first reported bioanalytical assay for the…”
Get full text

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin by van Andel, L., Rosing, H., Tibben, M. M., Lucas, L., Lubomirov, R., Avilés, P., Francesch, A., Fudio, S., Gebretensae, A., Hillebrand, M. J. X., Schellens, J. H. M., Beijnen, J. H.

“…Purpose Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients…”
Get full text

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer by van Andel, L., Fudio, S., Rosing, H., Munt, S., Miguel-Lillo, B., González, I., Tibben, M. M., de Vries, N., de Vries Schultink, A. H. M., Schellens, J. H. M., Beijnen, J. H.

“…Summary Plitidepsin (Aplidin®) is a marine-derived anticancer compound currently investigated in phase III clinical trials. This article describes the…”
Get full text

Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine by De Dios, C., Fudio, S., Lorenzo, A.

“…Summary What is known and Objective:  Combination therapy with valproic acid plus quetiapine is recommended as one of the first‐line approaches to treatment of…”
Get full text

361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors by Hidalgo, M, Boni, V, Tolcher, A, Smith, L, Cubillo, A, Rasco, D, Calvo, E, Amaya, A, Ordoñez, E, Patnaik, A, Cerda, S, Coronado, C, Fudio, S, Miguel-Lillo, B, Prados, R, Ortega, O, Soto-Matos, A, Papadopoulos, K.P

Get full text

Epileptic seizures caused by low valproic acid levels from an interaction with meropenem by Fudio, S., Carcas, A., Piñana, E., Ortega, R.

“…Summary A 55‐years‐old woman was diagnosed with pneumonia and was treated with meropenem; 5 days later she developed epileptic seizures. She had been treated…”
Get full text

Sublingual administration of tacrolimus in a renal transplant patient by Romero, I., Jiménez, C., Gil, F., Escuin, F., Ramirez, E., Fudio, S., Borobia, A., Carcas, A.

“…Summary Tacrolimus is used in renal and other organ transplantations for immunossupression therapy. Bioavailability of enterally administered tacrolimus is…”
Get full text

679P Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor by Moreno, I., Hernandez, T., Calvo, E., Fudio, S., Kahatt, C., Martinez, S., Iglesias, J., Calafati, R.O., Pérez Ramos, L., Montilla, L., Zeaiter, A., Lubomirov, R.

Get full text

671P Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors by Goel, S., Provencio Pulla, M., De Miguel Luken, M.J., Ghalib, M., Calvo de Juan, V., Hammami, M.B., Vikash, S., Maitra, R., Chaudhary, I., Martinez, S., Kahatt, C., Extremera, S., Fudio, S., Zeaiter, A.

Get full text

27O Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) by Garcia-Carbonero, R., Cote, G.M., Le Cesne, A., Anton-Pascual, B., Gordoa, T. Alonso, Gonzalez, A. Falcon, Torralvo, A. Gil, Martinez, S., Siguero, M., Cullell, M., Fudio, S., Zeaiter, A., Cerrillo, J. Molina

Get full text

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas by Aspeslagh, Sandrine, Stein, Mark, Bahleda, Rastilav, Hollebecque, Antoine, Salles, Gilles, Gyan, Emmanuel, Fudio, Salvador, Extremera, Sonia, Alfaro, Vicente, Soto-Matos, Arturo, Soria, Jean-Charles

“…This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced…”
Get full text

Pharmacokinetics and excretion of ^sup 14^C–Plitidepsin in patients with advanced cancer by van Andel, L, Fudio, S, Rosing, H, Munt, S, Miguel-lillo, B, González, I, Tibben, M M, de Vries, N, de Vries Schultink, A H; M, Schellens, J H; M, Beijnen, J H

“…Plitidepsin (Aplidin®) is a marine-derived anticancer compound currently investigated in phase III clinical trials. This article describes the distribution,…”
Get full text

Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine: Parkinsonism due to VPA and QTP interaction by De Dios, C., Fudio, S., Lorenzo, A.

Get full text

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14 C-plitidepsin by van Andel, L, Rosing, H, Tibben, M M, Lucas, L, Lubomirov, R, Avilés, P, Francesch, A, Fudio, S, Gebretensae, A, Hillebrand, M J X, Schellens, J H M, Beijnen, J H

“…Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients received a 3-h…”
Get full text

Pharmacokinetics and excretion of 14 C-Plitidepsin in patients with advanced cancer by van Andel, L, Fudio, S, Rosing, H, Munt, S, Miguel-Lillo, B, González, I, Tibben, M M, de Vries, N, de Vries Schultink, A H M, Schellens, J H M, Beijnen, J H

“…Plitidepsin (Aplidin®) is a marine-derived anticancer compound currently investigated in phase III clinical trials. This article describes the distribution,…”
Get full text

CASE REPORT: Epileptic seizures caused by low valproic acid levels from an interaction with meropenem by Fudio, S, Carcas, A, Pinana, E, Ortega, R

“…A 55-years-old woman was diagnosed with pneumonia and was treated with meropenem; 5 days later she developed epileptic seizures. She had been treated with…”
Get full text

Sublingual administration of tacrolimus in a renal transplant patient: Efficacy and safety of tacrolimus administration by Romero, I., Jiménez, C., Gil, F., Escuin, F., Ramirez, E., Fudio, S., Borobia, A., Carcas, A.

Get full text